MYD88 and Waldenstrom macroglobulinemia: On the other hand, a point mutation within TIR domain of MyD88 can lead to the constitutive activity of MyD88 that is a survival signal for proliferation in DLBC lymphoma cells, particularly in Waldenstrom’s macroglobulinemia (8–10).